Lorecivivint Shows Promising Efficacy for Managing Knee …
Nov 19, 2024 · Lorecivivint (LOR) demonstrated significant efficacy and safety for managing symptoms of moderate to severe knee osteoarthritis (OA) and improving patient reported outcomes (PROs), according to study results presented at the American College of Rheumatology (ACR) Convergence 2024, held from November 14 to 19, in Washington, DC.
FDA to Review Sublingual Cyclobenzaprine for Fibromyalgia …
Dec 30, 2024 · The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.
Metformin Shows Promise for Reducing Symptoms of Sjögren …
Nov 21, 2024 · Metformin may improve salivary gland function and reduce ocular symptoms among patients with Sjögren syndrome, according to study results presented at the American College of Rheumatology (ACR) Convergence 2024, held from November 14 to 19, in Washington, DC.. Sjögren syndrome is a systemic autoimmune disorder marked by …
FDA Roundup: Rheumatology Drug Alerts 2024
Mar 5, 2024 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.
ACR Releases 2024 Guideline Summary for Lupus Nephritis
Nov 25, 2024 · Recommended treatment includes pulse intravenous glucocorticoids (250-1000 mg/day for 1-3 days) transitioning to oral dosing (≤0.5 mg/kg/day), with the goal of tapering to a dose of 5 mg/day or less by 6 months.
TNX-102 SL Reduces Fibromyalgia Pain, Improves Sleep and …
Nov 15, 2024 · Additionally, FIQR Symptoms (P =.000002) and Function (P =.001) scores, PROMIS Sleep Disturbance (P =.0000001) and Fatigue (P =.00009) scores, and sleep quality measures (P =.0007) improved with TNX-102 SL treatment.Compared with placebo, TNX-102 SL also appeared to improve sexual function among women, according to total Changes in …
Rare and Unusual Clinical Presentations of Gout
Apr 19, 2024 · Gout is a type of inflammatory arthritis characterized by the deposition of monosodium urate crystals and the formation of tophi in tissues, typically in or around the joints. 1 Gout occurs more commonly in men compared with women 2 and “usually presents with sudden onset of severe pain, redness, and swelling of a single joint, most often in the feet, ankle, or …
Increased Risk for Cancer Observed in Abatacept-Treated …
The use of abatacept as an initial biologic disease-modifying antirheumatic drug (bDMARD) for the treatment of patients with rheumatoid arthritis (RA) is associated with a slightly elevated risk for cancer overall, and in particular for nonmelanoma skin cancer, compared with the use of other bDMARDs, according to the results of a population-based, real-world cohort study published in …
2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
Jan 13, 2020 · The American College of Rheumatology and the European League Against Rheumatism have developed and validated classification criteria for immunoglobulin G4-related disease (IgG4-RD). The new criteria have been published in the Annals of the Rheumatic Diseases.. According to the researchers, the classification of IgG4-RD requires correlating …
Ehlers-Danlos Syndrome - Rheumatology Advisor
Aug 10, 2022 · Ehlers-Danlos syndrome is a group of inherited connective tissue disorders that primarily affects the skin, joints, and blood vessel walls1 but can affect every organ system and result in significant morbidity and mortality. Typical clinical manifestations are skin hyperelasticity, hypermobility of joints, the fragility of blood vessels, and atrophic scarring. Hypermobility …